Boston, MA – January 4, 2022 – SVB Securities, a leading investment bank serving the innovation economy, announced today that David Risinger, CFA, has joined the firm’s healthcare equity research team covering biopharmaceutical companies.
David joins SVB Securities as a Senior Managing Director reporting to Director of Research, Jim Kelly. David’s most recent Wall Street role was the Head of US Major and Specialty Pharmaceuticals Equity Research for Morgan Stanley & Co. Prior to that, David held roles at Merrill Lynch & Co. and Dillon, Read & Co.
“David is a strong addition to SVB Securities, building upon our leadership across the healthcare industry,” said Jim Kelly. “His wealth of expertise covering the biopharma industry and his depth of relationships will serve to elevate our offerings for our clients and partners.”
Risinger stated: “I am excited to join SVB Securities to continue to develop its offering in biopharma research. This is a tremendous opportunity to work with a talented team that has proven its leadership in healthcare equity research and its commitment to producing a deep and differentiated research product for its clients.”